PDF herunterladen
Open Access
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2021; 42(02): 182-189
DOI: 10.1055/s-0041-1732825
How I Treat

How I Treat Adult Acute Myeloid Leukemia

Authors

  • Tapan K. Saikia

    1   Department of Medical Oncology, Prince Aly Khan Hospital, Mumbai, Maharashtra, India Medical ,Oncology Prince Aly Khan Hospital, Mumbai, Maharashtra, India .
Weitere Informationen
Auch verfügbar auf
  Lizenzen und Reprints
Preview

Introduction

In the mind of a reader, the first query would be, do I need to read another review article written by an Indian physician when I get to read everything on the multiple platforms on the internet? Such reaction is a valid one, given the avalanche of information and limited time available to read. Nevertheless, on request of the editorial board I accepted the challenge, and have included some relevant Indian publications.

Acute myeloid leukemia (AML) is a heterogeneous disorder and a very challenging pathology, though not fully unraveled yet.[1] [2] [3] [4] [5] While nonrandom cytogenetic and molecular abnormalities have provided opportunity for a better classification, we still have a sizeable number of cases in whom the pathology is poorly understood, and they continue to receive old chemotherapy regimens and hematopoietic stem cell transplantation (HSCT) whenever possible. Additionally, incidence of Myelodysplastic syndrome (MDS) associated AML and therapy-related AML is not insignificant; a subset of patient pausing maximum challenge.[6] [7] [8]

Acute promyelocytic leukemia (APL) can now be treated very effectively with nonchemotherapy-based regimens and a small subset deriving added benefit from inclusion of chemotherapy drugs like daunorubicin, idarubicin, and antibody drug conjugate gemtuzumab ozogamycin (GO).[9] [10] [11] [12] I will not discuss about APL in this review, as it needs a dedicated article.



Publikationsverlauf

Artikel online veröffentlicht:
06. August 2021

© 2021. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India